Cassava Agrees to Pay $40M Fine to Resolve SEC Probe as Company Hit With New Lawsuit
Despite the settlement, the Securities and Exchange Commission on Thursday sued Cassava Sciences in the Western District Court of Texas, claiming that the company misled investors regarding the Phase IIb performance of its Alzheimer’s disease drug candidate.
Cassava's Stock Drops After It Agrees to Pay $40M to Settle SEC Alzheimer's Claims
Key Takeaways Cassava Sciences and two former executives agreed to pay more than $40 million in a settlement with the SEC.The SEC said that Cassava made misleading statements about a clinical trial of its Alzheimer’s disease drug.
SEC Charges Cassava Sciences Over Manipulated Alzheimer's Trial Data, Company And Former Execs Agree To Pay Penalty
Alzheimer’s drug developer Cassava Sciences Inc (NASDAQ:SAVA), its founder Remi Barbier, and former Senior VP of Neuroscience Lindsay Burns have agreed to pay over $40 million to resolve SEC charges over misleading statements related to a Phase 2 trial of the company’s controversial Alzheimer’s drug,
Cassava Sciences and former execs, facing SEC charges for misleading claims, agree to fines
Cassava and former executives were charged Thursday by the SEC with making misleading claims in 2020 about trials for the Alzheimer's drug simufilam, and agreed to pay fines.
Cassava Sciences Shares Lower Premarket on $40M Penalty to Settle Doctored Data Claims
The SEC also said Dr. Hoau-Yan Wang, a Cassava consultant, was charged with manipulating the reported clinical trial results. Without admitting or denying the violations, Wang agreed to cease and desist from future violations and to pay a monetary penalty, the SEC said.
Cassava settles SEC charges related to Alzheimer’s candidate for $40M
Cassava Sciences settles SEC charges for $40M over misleading Alzheimer's drug trial results, ex-CEO and SVP also face negligence charges.
Cassava Sciences shares drop in pre-open trade after $40 mln SEC settlement
Shares of Cassava Sciences, Inc (NASDAQ:SAVA) dropped 11.5% in pre-open trade on Friday following the company's statement ...
FierceBiotech2h
Cassava, former execs ink SEC deal to resolve allegations around misleading Alzheimer's data drop
Cassava Sciences has agreed to pay $40 million to resolve an investigation into claims it made m | Cassava Sciences has ...
alzheimersnewstoday22h
Simufilam found safe in review of ongoing Alzheimer’s clinical trials
After a third review of safety data, an independent board recommended two trials of simufilam for Alzheimer's continue ...
Cassava's Simufilam: Safe On The Outside, Scrambled On The Inside
Cassava's financial challenges and data integrity concerns remain critical. Learn why SAVA stock is rated a strong sell given ...
Cassava Sciences Resolves SEC Investigation
AUSTIN, Texas, Sept. 26, 2024 (GLOBE NEWSWIRE) -- (“Cassava” or the “Company”) (Nasdaq: SAVA), a biotechnology company ...
Cassava Sciences Announces Completion of an Interim Safety Review of Oral Simufilam On-going Phase 3 Trials
An Independent Data and Safety Monitoring Board (DSMB) Recently Evaluated the Interim Patient Safety Database for Oral Simufilam in On-going Phase 3 Trials. The DSMB Recommended Both Phase 3 Trials ...
Why I'm Avoiding Cassava Stock For Now
Cassava Sciences' stock rose 9% after completing a trial of its Alzheimer's drug, Simufilam, but the company's future remains ...